Iambic’s physics-informed NeuralPLexer is intended to enhance protein–ligand modeling, enabling broader exploration of ...
With the acquisition of Boston-based Revela, a leading biotech startup, and the establishment of ODDITY LABS, the company is at the vanguard, bringing a proven drug discovery technology into beauty ...
Drug discovery has long relied on two key strategies: target-based and phenotypic screening. Recombinant technologies and genomics opened the door to modern target-based drug discovery (TBDD), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results